| Literature DB >> 11737409 |
D Smith1, I Gow, R Colebunders, I Weller, S Tchamouroff, J Weber, F Boag, G Hales, S Adams, G Patou, D A Cooper.
Abstract
In a randomized placebo controlled trial 304 HIV infected patients with CD4 cell counts below 350 cells/microL received therapeutic vaccination with: alum placebo (Group I, n = 102), p24-VLP 500 microg (Group II, n = 101) or p24-VLP 1000 microg (Group III, n = 101) p24-VLP monthly for six months. Over one year the average change in CD4 cell count did not differ significantly between groups (-32, -40 and -52 cells per microL respectively). There was also no difference between groups in progression to CDC category B or C events, or in adverse events. Therapeutic vaccination with p24-VLP does not affect CD4 cell decline in patients with advanced HIV infection.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11737409 DOI: 10.1046/j.1468-1293.2001.00080.x
Source DB: PubMed Journal: HIV Med ISSN: 1464-2662 Impact factor: 3.180